DCx sees potential to build multifunctional ADCs using the same technology Repare used to create its small molecule synthetic lethal therapies.

VERAXA Biotech AG ( VERAXA) has entered a co-discovery alliance with OmniAb, Inc. for the development of a novel bispecific antibody drug conjugate (bsADC) program targeting solid tumors.

OBI Pharma has received clearance from the US Food and Drug Administration (FDA) for an investigational new drug (IND) ...

Concerns around the proposed US Biosecure Act, lingering trade tensions, and the spectre of potential US tariffs are ...

Continued oncology pipeline advancement with a strategic focus on two priority pan-tumor programs: next-generation immunomodulator BNT327, a bispecific antibody targeting PD-L1 and VEGF-A1, and mRNA c ...

The leucine-rich repeat-containing protein 15 (LRRC15) is a cell surface protein involved in cell-cell and cell-matrix interactions, with limited expression in normal tissues.

Following clearance from the FDA, a phase 1/2 study will assess OBI-902 in Trop-2-overexpressing solid tumors, with plans for ...

The EMA has recommended extensions to the marketing authorizations for Adcetris, used to treat Hodgkin lymphoma, and ...

DB-1305/BNT325 was generally well tolerated and exhibited “very encouraging and durable antitumor activity in ovarian cancer patients,” said Maria Rubinstein, MD.

BOSTON and LONDON, May 01, 2025 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced ...